|17th February 2021||Briggs Morrison||4,761||Open or private purchase||$21.00||$99,981.00|
|8th February 2021||Briggs Morrison||35,156||Open or private sale||$20.55||$722,403.07|
|8th February 2021||Briggs Morrison||35,156||Exercise of derivative||$7.20||$253,123.20|
|3rd February 2021||William Meury||16,000||Grant/award etc.||$0.00|
|3rd February 2021||Fabrice Egros||16,000||Grant/award etc.||$0.00|
|3rd February 2021||Jennifer Jarrett||16,000||Grant/award etc.||$0.00|
|3rd February 2021||Pierre Legault||16,000||Grant/award etc.||$0.00|
|3rd February 2021||Keith Katkin||16,000||Grant/award etc.||$0.00|
|1st February 2021||Michael A Metzger||15,000||Open or private sale||$20.19||$302,799.00|
|1st February 2021||Michael A Metzger||15,000||Exercise of derivative||$7.20||$108,000.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005.